Source of this article: Times Weekly Author: Han Liming
The world's first new crown prevention drug has been approved for import.
According to Haikou Customs on July 5, the Boao Airport Customs affiliated to Haikou Customs has completed the approval of special entry items for the first time imported by my country, with a total value of 21.9802 million yuan. The drug is developed and produced by AstraZeneca and is mainly used for the prevention of novel coronavirus pneumonia in adults and adolescents (≥12 years old, weight ≥40 kg).
media disclosed that Ruikang Pharmaceutical investor relations department relevant person said that the company has been working with AstraZeneca for a long time and should be able to get Evusheld's mainland Chinese agent, but the company should not be the only agent. It is expected that AstraZeneca will find several agents. In the afternoon of July 6, Ruikang Pharmaceutical (002589.SZ) closed at the daily limit until the closing, closing at 4.28 yuan per share, with a total market value of 6.44 billion yuan.
On July 6, a reporter from the Times Weekly called Ruikang Pharmaceutical Investor Relations Department many times, and the phone number was busy.
Evusheld is a combination of two long-acting monoclonal antibodies. On December 8, 2021, it was authorized by the U.S. Food and Drug Administration (FDA) for pre-exposure prevention in adults and adolescents (12 years old and over, weighing 40 kg or more) who are not suitable for receiving the COVID-19 vaccine or who are insufficient immune response to the COVID-19 vaccine.
Evusheld is the only antibody therapy authorized in the United States to prevent COVID-19 before exposure, and it is also the only COVID-19 antibody that is injected through intramuscular injection. It is worth noting that people who have been infected with SARS-CoV-2 virus or who have been in close contact with the infected person in recent should not receive this therapy.
AstraZeneca China official website disclosed that compared with placebo, the risk of symptoms of COVID-19 in patients treated with Evusheld was statistically significantly reduced (preliminary analysis was 77%, and the median six-month follow-up was 83%), and the virus protection effect lasted for at least six months. To clarify the length of complete protection provided by Evusheld, longer follow-up is required.
On April 22, 2022, AstraZeneca China official website released a message saying that during the 6-month follow-up period, the subjects in the Evusheld group did not have severe symptoms of new crown or related deaths.
On July 4, 2022, the official microblog of the Management Committee of Boao Lecheng International Medical Tourism Pilot Zone in Hainan, "Lecheng Pilot Zone Management Bureau" shows that Evusheld has not yet been launched in my country. According to the relevant policies of " Nine in the National 19 ", it can be used in Boao Lecheng Pilot Zone. The new drugs have now been implemented in Ruijin Hainan Hospital and Boao Super Hospital . Those who need it can make an appointment to consult.
Times Weekly reporter learned from Ruijin Hainan Hospital that the hospital will receive a batch of Evushelds on July 9, and you can make an appointment by phone at present. Evusheld needs to be intramuscularly in two different parts at one time, and should be hospitalized for one night after the injection. The drug cannot be settled using medical insurance, and the price of two shots is 13,300 yuan.
